Clinical trial NCT05215483: Availability and Advice on Test Uptake During the COVID-19 Pandemic: a Vignette Study.
Official title: Availability and Advice on Test Uptake During the COVID-19 Pandemic: a Vignette Study on Lateral Flow Testing Policy in the Netherlands.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Keywords: Test intentions
Lateral Flow test uptake
Lead sponsor: National Institute for Public Health and the Environment (RIVM)
Sponsor class: OTHER_GOV
First posted: 2022-01-31
Enrollment: 3270
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Intervention model description: In an online randomised multi-factorial survey (vignette study) participants are randomised to assess four scenario's. Between subject testing advise is randomised (IV1; 2 levels) and the availability of LFT (IV2; 2 levels). Within subject we asked participants to assess their most likely behaviour on day 1 of symptoms and day 3 of unchanged symptoms (IV3; 2 levels). Corona-related symptoms are randomly presented (IV4; 4 levels) and new incidences of symptoms are presented in additional vignettes describing new months (IV5; 4 levels).
Primary purpose: PREVENTION

Brief summary: Lateral Flow Testing (LFT) use for COVID-19 related symptoms continues to rise, despite governmental advice to test at a test facility. In this study we investigate whether 1) adjusting the governmental testing advice will lead to a collective increase of people who test with COVID-19 symptoms and if this leads to a higher strategy sensitivity.

Detailed description: In an online randomised multi-factorial survey (vignette study) participants are randomised to assess four scenario's. Between subject testing advise is randomised (IV1; 2 levels) and the availability of LFT (IV2; 2 levels). Within subject we asked participants to assess their most likely behaviour on day 1 of symptoms and day 3 of unchanged symptoms (IV3; 2 levels). Corona-related symptoms are randomly presented (IV4; 4 levels) and new incidences of symptoms are presented in additional vignettes describing new months (IV5; 4 levels).

Subjects are asked to immerse themselves in the scenario's before answering what their most likely behaviour would be: a) go to a test facility b) use a LFT c) wait and see or 4) no test. Participants who didn't choose the test facility on day 1 were presented with the same vignette on day 3 with unchanged symptoms, and were asked their most likely behaviour again.

After assessing the scenario's, participants fill in a questionnaire assessing demographics, behavioural determinants related to test behaviour, vaccine status, current symptoms and previous experience with Corona and testing.

The primary outcomes is defined as the average strategy sensitivity over time and therefore the chance of detecting a Covid-infection. Average strategy sensitivity is calculated by converting the choice of testing behaviour into the corresponding sensitivity score (PCR =1, LFT day 1 = .8, LFT day 3 = .7, wait and see and no test = 0), averaged over four scenario's.

Our primary hypothesis is:

1. Adjusting the governmental testing advice will lead to a higher strategy sensitivity.

   In follow-up analysis we will explore the following hypothesis:
2. Availability of LFT at home will lead to a higher strategy sensitivity.
3. The type of corona related symptoms (mild or severe) are predictive of the type of test used.
4. When confronted with a new incidence of corona-related symptoms over time, strategy sensitivity will decline.

Eligibility criteria: Participants were recruited from an online research panel representative for the Dutch population.

Inclusion Criteria:

* non

Exclusion Criteria:

* non

Primary outcomes:
measure: Average strategy sensitivity over time: day 1
timeFrame: average strategy sensitivity day 1
measure: Maximum average strategy sensitivity over time
timeFrame: maximum average strategy sensitivity day 1 and 3
Secondary outcomes:
measure: Willingness to test day 1
timeFrame: Day 1
measure: Willingness to test - maximum
timeFrame: Day 1 and 3
measure: Type of test chosen day 1
timeFrame: Day 1
measure: Type of test chosen day 3
timeFrame: Day 3
Other outcomes:
Locations:
city: Bilthoven
country: Netherlands
facility: National Institute for Public Health and the Environment
state: Utrecht
Study officials:
affiliation: RIVM
name: Marijn de Bruin, prof
role: STUDY_CHAIR
References: